Clene's Submission of Briefing Book to FDA for CNM-Au8 in ALS Treatment

What is Clene’s plan regarding the FDA?

Clene plans to submit a briefing book to the U.S. Food and Drug Administration by July 13, 2024, as part of the process to support approval for CNM-Au8 as a treatment for ALS.

What is the purpose of the Type C interaction with the FDA?

The Type C interaction is aimed at obtaining FDA feedback on the potential pathway for a new drug application for CNM-Au8 as a treatment for ALS via the accelerated approval process.

What does the briefing book include?

The briefing book includes new post-hoc analyses of data from completed clinical trials and addresses comments made by the FDA during a previous meeting in late 2023.

What is CNM-Au8?

CNM-Au8 is Clene’s primary therapeutic asset, a highly concentrated aqueous suspension of catalytically active, clean-surfaced, faceted gold nanocrystals aimed at treating neurodegenerative diseases like ALS.

When is the Type C interaction scheduled?

The Type C interaction is scheduled for the third quarter of 2024.

Why is this submission important?

This submission is important as it represents a step forward in seeking FDA approval for CNM-Au8 as a treatment for ALS, potentially offering a new therapeutic option for patients.

Where can I find more information about Clene?

More information about Clene can be found in the company’s newsroom at https://ibn.fm/CLNN.

Who is involved in this process?

Clene and its wholly owned subsidiary Clene Nanomedicine Inc. are involved in this process, along with the U.S. Food and Drug Administration.

What are the implications of this submission?

The implications include potential FDA approval of CNM-Au8 for ALS treatment, which could significantly impact patients suffering from this neurodegenerative disease.

How does CNM-Au8 work?

CNM-Au8 is designed to enhance mitochondrial health and protect neuronal function, targeting mitochondrial dysfunction and NAD+ decline associated with neurodegenerative diseases like ALS.